Want to see PRPH full AI Analyst Report?
PRPH Stock Chart & Stats
$0.02
<$0.01(4.95%)
At close: 4:00 PM EDT
$0.02
<$0.01(4.95%)
Day’s Range― - ―
52-Week Range<$0.01 - $5.36
Previous CloseN/A
Volume53.96K
Average Volume (3M)300.22K
Market Cap
$163.08K
Enterprise Value$10.39M
Total Cash (Recent Filing)$20.00K
Total Debt (Recent Filing)$9.12M
Price to Earnings (P/E)―
Beta1.97
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.44%
Share Statistics
EPS (TTM)-3.12
Shares Outstanding18,120,030
10 Day Avg. Volume583,482
30 Day Avg. Volume300,220
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.09
Price to Sales (P/S)0.88
P/FCF Ratio-0.46
Enterprise Value/Market Cap63.71
Enterprise Value/Revenue3.29
Enterprise Value/Gross Profit20.10
Enterprise Value/Ebitda-1.45
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)10.4
Revenue Forecast (FY)$41.69M
Bulls Say, Bears Say
Bulls Say
Diversified Operating ModelThe combination of consumer products and diagnostic laboratory services gives ProPhase Labs exposure to more than one healthcare-related revenue stream. If both activities are maintained and commercial execution improves, this breadth could support business resilience over the coming quarters.
Sizable Asset BaseA sizable asset base provides operating resources that may support restructuring, product development, or continued laboratory activity. Although current returns are deeply negative, these assets represent a foundation that could become more productive if revenue and cost controls recover.
Losses Improved From 2024Improvement from the very large 2024 net loss indicates that profitability has not deteriorated monotonically. If this progress continues alongside revenue stabilization and cost reductions, it could provide an important base for rebuilding earnings quality over the next several quarters.
Bears Say
Severe Revenue ContractionThe collapse in revenue indicates a major contraction in the company’s commercial scale and limits its ability to absorb fixed operating costs. Continued negative growth would weaken both segments’ capacity to fund operations, invest in products, and rebuild sustainable earnings.
Deep Operating And Net LossesExtremely negative operating and net margins show that the current cost structure is far larger than the revenue base. This makes profitability recovery dependent on substantial revenue rebuilding or cost reductions, while ongoing losses can further erode capital and financial flexibility.
Persistent Cash BurnCash generation is a major structural weakness because operating and free cash flow remain deeply negative and have worsened from approximately -$8.3M in 2025. Sustained cash consumption increases dependence on external financing and constrains the company’s ability to fund operations internally.
Prophase Labs News
PRPH FAQ
What was Prophase Labs’s price range in the past 12 months?
Prophase Labs lowest stock price was <$0.01 and its highest was $5.36 in the past 12 months.
What is Prophase Labs’s market cap?
Prophase Labs’s market cap is $163.08K.
When is Prophase Labs’s upcoming earnings report date?
Prophase Labs’s upcoming earnings report date is Nov 05, 2026 which is in 6 days.
How were Prophase Labs’s earnings last quarter?
Prophase Labs released its earnings results on Aug 06, 2026. The company reported -$0.218 earnings per share for the quarter.
Is Prophase Labs overvalued?
According to Wall Street analysts Prophase Labs’s price is currently Overvalued.
Does Prophase Labs pay dividends?
Prophase Labs pays a Quarterly dividend of $0.3 which represents an annual dividend yield of 1.44%. See more information on Prophase Labs dividends here
What is Prophase Labs’s EPS estimate?
Prophase Labs’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Prophase Labs have?
Prophase Labs has 18,120,030 shares outstanding.
What happened to Prophase Labs’s price movement after its last earnings report?
Prophase Labs reported an EPS of -$0.218 in its last earnings report. Following the earnings report the stock price went up 6.977%.
Which hedge fund is a major shareholder of Prophase Labs?
Currently, no hedge funds are holding shares in PRPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Prophase Labs
ProPhase Labs, Inc., founded in 1989 in Garden City, New York (and previously known as The Quigley Corporation), operates as a diversified company with two main areas of focus: Consumer Products and Diagnostic Services. Through its Consumer Products division, ProPhase Labs is actively involved in the entire process—from researching and developing to manufacturing, distributing, marketing, and selling—a range of over-the-counter (OTC) healthcare items and nutritional supplements within the United States. Notable offerings include dietary supplements like Legendz XL, which supports male sexual health, and Triple Edge XL, formulated to enhance energy and stamina. The Diagnostic Services segment provides crucial testing solutions, including PCR tests for SARS-CoV-2 (COVID-19) and its variant mutations, using both saliva and nasal swab collection methods. This segment also offers molecular testing for other respiratory pathogens and supplies personal genomics products and services. Additionally, ProPhase Labs extends its capabilities by providing comprehensive contract manufacturing services, covering product development, pre-commercialization activities, production, warehousing, and distribution. The company's diverse products and services reach consumers through a broad network of national chain drug stores, various regional retailers, and online platforms.
Technical Analysis
Ownership Overview
―
Insiders
0.12% Mutual Funds
0.47% Other Institutional Investors
99.42% Public Companies and
Individual Investors